Home | Welcome to Contract Pharma   
Last Updated Saturday, August 30 2014
Print

Search Results for 'Financial Reports: Biogen Idec'

Search For:
Refine by Dates:
From: To:
Past 7 Days        Past 30 Days
Refine By Content:

Search Results:

Published July 23, 2014
MS drug TECFIDERA drives growth in the quarter Read More »
Published April 23, 2014
51% growth driven by MS franchise Read More »
By Kristin Brooks
Published January 29, 2014
Expanded MS franchise drives growth Read More »
Published July 25, 2013
Revenues up 21% in the quarter with Tecfidera launch Read More »
By Gil Roth
Published January 28, 2013
MS franchise continues growth trend Read More »
Published October 25, 2012
Revenues up 6% in the quarter on Avonex boost Read More »
Published October 31, 2011
Revenues up 11% Read More »
Published April 21, 2011
Growth in the quarter was primarily driven by Tysabri revenues, up 15% to $251 million, and Avonex sales, up 8% to $642 million. Read More »
Published July 16, 2009
Growth in the quarter was driven by Tysabri sales, up 27% to $188 million, and Avonex sales, up 12% to $591 million. Read More »
Published February 6, 2008
Biogen Idec 4Q Revenues: $893 million (+26%) 4Q Earnings: $201 million (+84%) FY Revenues: $3.2 billion (+18%) FY Earnings: $638 million (+193%) Comments: FY07 growth was primarily driven by Tysabri, Rituxan and Avonex sales. Through t… Read More »
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On